Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Momenta’s Q2 losses narrow
For the six months ended June 30, 2008, the company reported a net loss of $28.3 million,compared with a net loss of $35.7 million in the same period
For the six months ended June 30, 2008, the company reported a net loss of $28.3 million,compared with a net loss of $35.7 million in the same period
The data safety monitoring board meets every six months to review unblinded safety data from the toremifene Phase III clinical trials. Nearly 1,600 patients with high grade prostatic
Exelixis said that it has submitted the corresponding data report to GlaxoSmithKline (GSK). Under the agreement, GSK has 90 days to review the data and decide whether to
Under the terms of the relationship, Corgenix’s AspirinWorks product will be used to assess aspirin effect as part of SpectraCell’s cardiovascular risk assessment services. The collaboration will allow
This submission is the result of clinical testing and drug-device interaction studies performed over the past 18 months. The sNDA filing also references the 510(k) previously filed by
In association with the financing, Kenneth Noonan, partner at LEK Consulting, has been named non-executive chairman of Intercept’s board of directors. In this capacity he succeeds James Mervis
The data supporting the product includes a clinical study in insomnia patients that was completed in October 2007. That study showed that Sublinox induced sleep 30% earlier compared
The iclaprim marketing authorization application (MAA) contains data from 15 clinical studies, including two well-controlled multinational pivotal Phase III trials (Assist-1 and Assist -2, in which approximately 1,000
The new center will will open on September 2, 2008 and provide medical imaging services to more than 50 medical clinics, including Fairview Crosstown Clinic, according to Suburban
UVaCide was formed in 2004 to develop a series of medical technology solutions utilizing next generation laser technologies. After years of comprehensive research into various light-based solutions, UVaCide